{"id":"3b06bc18104f","type":"article","url":"https://hartvaat.nl/2020/10/01/crp-sst2-en-gdf-15-multimarker-voor-prognostische-stratificatie-bij-stabiel-hf/","title":"CRP, sST2 en GDF-15 multimarker voor prognostische stratificatie bij stabiel HF","title_en":"Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","hs-crp","nt-probnp"],"journal":"ESC heart failure","doi":"10.1002/ehf2.12680","source_url":"https://doi.org/10.1002/ehf2.12680","authors":["Nils Kuster","Fabien Huet","Anne-Marie Dupuy","Mariama Akodad","Pascal Battistella","Audrey Agullo","Florence Leclercq","Eran Kalmanovich","Alexandra Meilhac","Sylvain Aguilhon","Jean-Paul Cristol","Francois Roubille"],"significance":5,"published":"2020-10-01","source_date":"2020-10-01","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"This study evaluated a multimarker approach using CRP, sST2, and GDF-15 for prognostic stratification in stable heart failure, showing that combining inflammatory and remodeling biomarkers improves risk prediction.","created":"2026-07-03T10:28:47Z","updated":"2026-07-03T13:27:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie naar een multimarker benadering met CRP, sST2 en GDF-15 voor prognostische stratificatie bij stabiel hartfalen.","abstract_original":"AIMS: Inflammation and cardiac remodelling are common and synergistic pathways in heart failure (HF). Emerging biomarkers such as soluble suppression of tumorigenicity 2 (sST2) and growth differentiation factor-15 (GDF-15), which are linked to inflammation and fibrosis process, have been proposed as prognosis factors. However, their potential additive values remain poorly investigated. METHODS AND RESULTS: Here, we aimed at evaluating inflammatory and remodelling biomarkers to predict both short-term and long-term mortality in a population with chronic HF in comparison with other classical clinical or biological markers (i.e. N terminal pro brain natriuretic peptide, hs-cTnT, C-reactive protein) alone or using meta-analysis global group in chronic HF risk score in a cohort of 182 patients followed during 80 months (interquartile range: 12.3-90.0). Proportional hazard assumption does not hold for sST2 and C-reactive protein, and follow-up was split into short term (less than 1 year), midterm (between 1 and 5 years), and long term (after 5 years). In univariate analysis, C-reactive protein and sST2 were predictive of short-term mortality but not of middle term and long term whereas GDF-15 was predictive of short and mid-term but not of long-term mortality. In a multivariate model after adjustment for meta-analysis global group in chronic HF score including the three markers, only sST2 was predictive of short-term mortality (P = 0.0225), and only GDF-15 was predictive of middle term mortality (P = 0.0375). None of the markers was predictive of long-term mortality. CONCLUSIONS: Our results demonstrate that both sST2 and GDF-15 significantly improve the prognosis evaluation of HF patients and suggest that the value of GDF-15 is more sustained overtime and could predict middle term events."}